Sukhjit Starch & Chemicals Ltd

- The company is exploring greenfield and brownfield expansion opportunities but has not committed to any new plant setup yet. - Bhavdeep Sardana mentioned that any large project would be commissioned over 24 to 30 months, with significant contributions from internal resources. - The company has a very comfortable debt-to-equity ratio (around 0.16) and is willing to increase debt up to about 0.6 if needed for expansion. - Long-term debt is expected to continue reducing while reserves grow through operations. - Decisions on new capacity expansions or projects will consider debt levels carefully, and the company has the flexibility to choose the degree of debt funding. - There is no explicit mention of equity fundraising; the focus appears to be on prudent debt usage and internal accruals for funding expansions.

- The company is currently expanding capacity across various locations, including an ongoing 400 tons per day capacity expansion expected to be completed soon. - Aiming to ramp up capacity utilization in H2 of FY '25, with some volume growth expected to start in Q3 or early Q4. - Exploring both greenfield and brownfield expansion opportunities involving approximately 1,000 to 1,200 tons capacity. - Estimated capital outlay for new plants could be around INR 200 crores, depending on location and product mix. - Expansion projects are expected to be commissioned within 24 to 30 months, with flexibility in financing, leveraging both internal resources and manageable debt levels (comfortable debt-to-equity ratio below 0.6). - Possible initiation of new large-scale projects could begin as early as Q4 FY '24, subject to due diligence and market conditions.

- Company aims for a minimum of 5% to 6% revenue growth in FY '25, potentially more depending on raw material prices. - Volume growth expected to be around 10% by FY '25-'26, driven by capacity expansions and product enhancements. - Capacity utilization currently at 83%-85%; expansions expected to raise this with ramp-up mainly in H2 FY '25. - Long-term volume growth outlook remains positive, supported by favorable demand dynamics in sectors like FMCG, pharma, paper, and textile. - The company is hopeful for better growth in FY '26 than FY '25. - High-value product sales expected to recharge sales positively in coming quarters due to recovery in FMCG and pharma sectors. - Strategic initiatives include product diversification, capacity enhancement, and exploring greenfield and brownfield projects to sustain growth.

- The company anticipates positive volume growth going forward, targeting around 5-10% volume growth in FY '25 and FY '26, depending on capacity expansion progress. - Revenue growth is expected to be minimum 5-6% for FY '25, possibly higher, with conservative estimates of 6-8% growth if maize pricing remains stable. - Expansion of capacity by approximately 400 tons in various product lines is nearing completion, expected to positively impact volumes and margins in H2 FY '25. - Focus on high-value products (FMCG, pharma) is expected to recharge sales and improve profitability going ahead as these sectors show signs of recovery. - The company aims to improve operating margins by increasing starch utilization and moving up the value chain with enhanced product quality. - Long-term growth is supported by strategic greenfield/brownfield projects planned over 24-30 months, leveraging internal accruals and manageable debt levels. - Management expresses confidence in sustainable and profitable growth driven by strategic initiatives and market opportunities.

- The transcript does not explicitly mention the current or expected order book or pending orders for The Sukhjit Starch and Chemicals Limited. - The company discussed ongoing capacity expansions (approximately 400 tons increase) expected to be commercialized soon, indicating upcoming order fulfillment growth. - Relationships with FMCG players include quantity contracts with quarterly pricing but no fixed long-term contracts, implying flexible order-based engagement rather than fixed pending orders. - Management expressed optimism about volume growth and increasing demand in key sectors like FMCG and pharma but did not quantify pending orders. - Focus remains on strategically scaling capacity and meeting anticipated demand rather than disclosing specific order backlogs. In summary, no concrete details on current or pending orders are provided, but capacity expansions and client relationships suggest a growing and manageable order intake.